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Abstract
Background: Tuberculosis, caused by Mycobacterium tuberculosis (MTB), is the most notified disease in the world.
Development of resistance to first line drugs by MTB is a public health concern. As a result, there is the search for
new and novel sources of antimycobacterial drugs for example from medicinal plants. In this study we determined
the in vitro antimycobacterial activity of n-Hexane sub-fraction from Bridelia micrantha (Berth) against MTB H37Ra
and a clinical isolate resistant to all five first-line antituberculosis drugs.
Methods: The antimycobacterial activity of the n-Hexane sub-fraction of ethyl acetate fractions from acetone
extracts of B. micrantha barks was evaluated using the resazurin microplate assay against two MTB isolates.
Bioassay-guided fractionation of the ethyl acetate fraction was performed using 100% n-Hexane and Chloroform/
Methanol (99:1) as solvents in order of increasing polarity by column chromatography and Resazurin microtiter
plate assay for susceptibility tests.
Results: The n-Hexane fraction showed 20% inhibition of MTB H37Ra and almost 35% inhibition of an MTB isolate
resistant to all first-line drugs at 10 μg/mL. GC/MS analysis of the fraction resulted in the identification of twenty-
four constituents representing 60.5% of the fraction. Some of the 24 compounds detected included Benzene,
1.3-bis (3-phenoxyphenoxy (13.51%), 2-pinen-4-one (10.03%), N(b)-benzyl-14-(carboxymethyl) (6.35%) and the least
detected compound was linalool (0.2%).
Conclusions: The results show that the n-Hexane fraction of B. micrantha has antimycobacterial activity.
Background
Healthcare burden resulting from an estimated 13.3
million prevalent cases of tuberculosis (TB) and 2.32
million deaths [1] has been made worse by the emer-
gence of multidrug-resistant TB (MDR-TB). Although
tuberculosis is treatable, few alternative drugs are
available in cases where drug resistance is a problem.
Second-line drugs such as kanamycin, p-aminosalicy-
late, ethionamide and fluoroquinolones currently used
are either less effective or toxic [1]. There is therefore
an urgent need to discover and develop new anti-TB
drugs to target drug resistance, and improve the treat-
ment of latent TB [2].
Natural products isolated from terrestrial plants have
played a major role in the discovery of drugs against
infectious diseases [3]. Approximately 10% of the world’s
terrestrial plants, some being used medicinally, are
found in South Africa. However, few of these plants
have been investigated for anti-TB activity, yet TB is
one of South Africa’s biggest healthcare problems. In a
preliminary screening of selected South African plants
for antimycobacterial activity, we observed that the acet-
one extract of B. micrantha barks showed potent growth
inhibition of MTB with a MIC of 25 μg/mL [4].
B. micrantha (Euphorbiaceae) is commonly used tradi-
tionally for gastro-intestinal ailments, painful joints,
retained placenta, diabetes mellitus, syphilis, prehepatic
jaundice, tape worm abdominal pain, conjunctivitis,
headache, scabies, bloody diarrhoea, dysentery, emetic,
wound infection, coughs, threadworms, tonic for chil-
dren, sore eyes, epigastric pain, relief of headache,
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purgative diarrhoea and worms [5-7]. Essential oils have
long been used for a wide variety of medicine [8]. Anti-
microbial properties of essential oils have been well
documented [9,10]. Compounds found in Anethum
graveolens have been reported to have various degrees
of antimycobactetial activity [11].
In this study, we report on the effects of the n-Hexane
fraction, obtained from acetone extract of B. micrantha,
on the growth of mycobacteria. Furthermore, we charac-
terized constituents from this active fraction using
GC/MS.
Methods
Plant material, extraction and purification
The acetone extracts of B. micrantha barks were pre-
pared following a previously reported scheme [12].
Briefly, the air dried barks of the plant were pulverized
and extracted three times by maceration in acetone for
72 h at room temperature. The solvent extract was eva-
porated to yield a brownish viscous residue. The acetone
extracts were further extracted using ethyl acetate. The
ethyl acetate fraction (9 g) was further fractionated
using Gravity column chromatography with 100%
n-Hexane, 1% Methanol in Chloroform in order of
increasing polarity up to 5% Methanol in Chloroform,
then 100% Methanol to yield sixteen sub-fractions of
increasing polarity (F1-F16). Each sub-fraction was
tested for activity against MTB H37Ra and the resistant
isolate [13].
Mycobacteria used
MTB strain H37Ra (American Type Culture Collection
27294) and an MDR clinical isolate were used in the
present study. The first (H37Ra) is sensitive and the sec-
ond (a local isolate) is resistant to all five first-line anti-
tuberculosis drugs (streptomycin, isoniazide, rifampin,
ethambutol, and pyrazinamide). The clinical isolate was
isolated, identified, and characterized in the Mycobacter-
iology Laboratory at the University of Limpopo,
MEDUNSA Campus, Pretoria, South Africa from a
patient with advanced pulmonary tuberculosis [14].
Antituberculosis activity
Antimycobacterial bioassay was performed using the
Resazurin microplate assay (REMA) [15]. The fractions
were dissolved in DMSO to give a concentration of
1 mg/mL. Control experiments with organism and
decreasing concentration of DMSO were performed to
avoid DMSO affecting the toxicity of the fractions to
MTB. Suspensions of MTB H37Ra strains were prepared
at a concentration of about 105 cells/mL. One hundred
microlitre of the bacterial suspension was added to each
well of a microtiter plate together with the plant fraction
in Middlebrook 7H9 broth to a final volume of 200 μL,
and the final concentration of the n-Hexane fraction
ranged from 0.391 to 100 μg/mL. After incubation for
7 days, 20 μg/mL of Resazurin dye was added to the
control well. If the dye turned pink, indicating bacterial
growth, the dye was then added to all remaining wells
in the plate. The results were read the following
day using a microtiter plate reader (Bio-Rad 680, South
Africa). The same drug sensitivity procedure was applied
to the MDR isolate. For standard tests, the MIC
values of rifampin and isoniazid were determined each
time. The acceptable MIC ranges of the drugs were
0.0047-0.0095 and 0.05-0.1 μg/mL respectively [16]. The
experiments were done in triplicate and the average
concentrations were reported.
Phytochemical analysis of fractions
Chemical constituents of the extracts were analyzed by
thin layer chromatography (TLC) using aluminium-
backed TLC plates (Merck, silica gel 60 F254). The TLC
plates were developed with one of the four eluent sys-
tems, ethyl acetate/methanol/water (40:5.4:5): [EMW]
(polar/neutral); chloroform/ethyl acetate/formic acid
(5:4:1): [CEF] (intermediate polarity/acidic); benzene/
ethanol/ammonium hydroxide (90:10:1): [BEA] (non-
polar/basic) [17], Hexane/Ethyl acetate (150:1) [HE]
(non-polar). Development of the chromatograms was
done in a closed tank in which the atmosphere had
been saturated with the eluent vapour by lining the tank
with filter paper soaked with the eluent [18].
TLC analysis of the fractions
Visible bands were marked under daylight and ultravio-
let light (254 and 360 nm, Camac Universal UV lamp
TL-600) before spraying with freshly prepared vanillin
(0.1 g vanillin, 28 mL methanol, 1 mL sulphuric acid)
spray reagents [19]. The plates were carefully heated at
100°C for optimal colour development. Fraction (F1)
(200 mg) (100% n-Hexane fraction) and F5 (150 mg)
(1.75% Methanol in Chloroform) were identified as
putative pure compounds because only one band was
observed on TLC plates.
GC-MS analyses and identification of components
The GC-MS analyses was carried out using Hewlett-
Packard HP 5973 mass spectrometer interfaced with an
HP-6890 gas chromatograph with an HP5 column
(30 m × 0.25 mm id, 0.25 μm film thickness) and an
MS detector. The oven temperature was programmed
from 70°C (after 2 minutes) to 325°C at 4°C/min, final
temperature was held for 10 minutes at 240°C. The ion
source was set at 240°C and electron ionization at
70 Ev. Helium was used as the carrier gas (1 mi/min).
The split ratio was 1:25 with the scan range of 35 to
425 amu. Hexane fraction (1.0 μL), diluted in hexane
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was manually injected into the GC/MS. The compo-
nents of the oils were identified based on the compari-
son of their retention indices and mass spectra with the
standards, the Wiley 275 Library of Mass Spectra data-
base (Wiley, New York) of the GC/MS system and pub-
lished data [19-21].
Results
Plant material, extraction and purification
Nine grams of ethyl acetate fraction were collected from
30.412 g acetone extracts, showing 29.6% yield. The
n-Hexane fraction yields were calculated on a dry weight
basis as 0.5% (0.045 g/9 g × 100) and was analysed to
determine its constituents (Table 1). In order to identify
putative active compounds present within B. micrantha
n-Hexane fraction, we employed a gas chromatography/
mass spectrometry (GC/MS) system. Twenty-four deri-
vatives were present whose abundance was more than
0.1%, corresponding to N (b)-benzyl-14-(carboxymethyl),
Benzene, 1,3-bis (3-phenoxyphenoxy), 2-Pinen-4-one as
major compounds. All the compounds identified are
shown in Table 1. F5 was identified as 3-oxo-11a-
hydroxyolean-12-ene-30-oic acid when compared with
the standards on TLC.
Antituberculosis activity
The acetone extracts of B. micrantha that showed activity
on MTB isolates [4] was submitted to bioassay-guided
fractionation using column chromatography. Primary
fraction F1 (ethyl acetate fraction) showed antimycobac-
terial activity on MTB H37Ra. F1 was further fractionated
as mentioned above and showed an MIC value of
8.25 μg/mL against H37Ra MTB strain. The fraction also
inhibited the growth of the local MTB isolate resistant to
INH, STM, EMB, and RIF at a concentration of 50 μg/
mL. Statistical significance was observed only when F1
was compared with first line antibiotics (Odd ratio [OR]
= 1.84, 95% CI 1.37-2.46, p value for trends = 0.0012).
The final concentration of DMSO (2%) in the broth did
not show any inhibition of MTB.
Discussion
Plants have been used throughout history in traditional
medicines for the treatment of diseases worldwide.
Today, approximately two-thirds to three-quarters of
the world’s population are estimated to rely on medic-
inal plants as their primary source of medicines [22].
There has been an increasing interest in studying the
biological properties of plants and their derivatives for
discovering biologically active compounds [23,24]. Phy-
tochemicals with prominent pharmacological properties
which were not previously identified were discovered
from plant product [25]. They have been defined as
small organic biomolecules generally hydrophobic and
designated as naturally occurring antibiotics [26]. Coa-
gulation of cytoplasmic membrane, breakdown of proton
motive force, breakdown of electron flux and the cause
of imbalance in active transport are some of the antimi-
crobial mechanisms of phytochemicals [26].
The hexane fractions are known to contain essential
oils. Several studies have demonstrated that essential
oils hold therapeutic value in treatment of diseases and
are well tolerated [27-29]. The Hexane fractions in our
study demonstrated 80% inhibition at 30 μg/mL on clin-
ical isolate resistant to RIF, EMB, INH and STM and
more than 90% on MTB H37Ra.
In many essential oils, the antimicrobial activity is due
to the presence of isoprenes such as monoterpenes, ses-
quiterpenes or related alcohols and phenols [30]. The
activity of n-Hexane fraction of B. micrantha is probably
due to the presence of isoprenes identified by GC/MS in
our study. Monoterpenes have been shown to poses
antimycobacterial effect at lower (100 μg/mL) concen-
trations [31]. More specifically a-pinene was shown to
have a MIC of 64 μg/mL against MTB H37Rv [32].
Table 1 The phytochemicals of the n-Hexane fractions





MS + Tret identification
* *%
1 3.19 N(b)-benzyl-14-(carboxymethyl) 6.35
2 3.21 Benzene, 1.3-bis (3-
phenoxyphenoxy)
13.51
3 3.43 2-Phenyl-2-tipyl-acenapthenone 4.50
4 5.96 a-pinene 0.49
5 6.30 Camphene 0.14
6 8.28 1.8 cineole 0.91
7 11.32 Camphor 2.77
8 11.91 Endo-Borneol 1.76
9 12.23 Linalool 0.20
10 12.60 1-a-Terpineol 0.43
11 12.88 a-Caryophyllene oxide 0.95
12 12.94 Nopol 0.45
13 13.10 2-Pinen-4-one 10.03
14 15.12 (-)-Bornyl acetate 1.96
15 17.81 1 Tetradecanol (Fatty alcohol) 1.07
16 22.60 5-Octadecene 1.10
17 29.64 Hexadecanoic acid (Methyl
ester)
1.02
18 30.38 Palmitic acid 3.91
19 34.09 17-Pentatriacontene 1.51
20 36.27 Tritetracontane 1.36
21 36.88 5.beta.-Pregn-11-ene 1.71
22 38.76 4-Imidozolidinone 3.49
23 40.52 Naphthalene 1.06
24 40.82 Quinoline 1.58
TOTAL 60.55%
*Only the percentages over 0.1% are indicated.
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It was demonstrated that the physical properties of
essential oils significantly influences the actions of the
individual components, increasing or reducing antimi-
crobial efficacy [32]. The hydrophilic character of mono-
terpenes functional groups and the lipophilic character
of their hydrocarbon skeleton are of main importance in
the antimicrobial action of essential oil components
[33]. The disturbance of lipid fraction of the plasma
membrane could be the antibacterial activity of terpenes,
resulting in alterations of membrane permeability and
leakage of intracellular materials [34]. This effect may
also be a consequence of the interaction between the
major and minority components of essential oil. Essen-
tial oils need to be diluted in alcohols that enhance
their volatility and aroma. In determining where the
antimicrobial effect of n-Hexane fraction is derived
from, we tested 2% DMSO on both MTB isolates. The
antimycobacterial effect was found to be due to essential
oil as 2% DMSO did not inhibit growth of MTB.
B. micrantha stem bark was reported to be abortifa-
cient with potentially toxic effects probably due to the
presence of delphinidin and methyl salicylate [35].
Those two compounds were not observed among the
isolated essential oils in our study. The major compo-
nents of the essential oil in the present study were
Benzene, 1.3-bis (3-phenoxyphenoxy) (13.51%), and 2-
Pinen-4-one (10.13%). Antimycobacterial activities of
essential oils with 1,8 Cineole, camphor, a-Pinene, bor-
neol as major compounds were recently elucidated [36].
Although their percentage is low, the same compounds
were found in the n-Hexane fraction in our study. In a
study by Lamproti and co-workers [37], a-pinene,
a-terpineol, caryophyllene, were found to inhibit the
proliferation of tumor cells in vitro.
Conclusions
The essential oils and volatile compounds may provide
an important source of new antimycobacterial agents.
However, toxicity of these complex mixes should be
determined.
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